Table 3.

Association between genetic polymorphisms in the AhR, CYP1A2, NAT2, and NAT1 genes and risk for colorectal polyps, the TCPS, 2003-2005

GeneControls
Polyp type
Adenomatous only
Hyperplastic only
Concurrent adenomatous and hyperplastic
nnOR (95% CI)*nOR (95% CI)*nOR (95% CI)*
AhR (rs2066853)
    GG1,1094161.0 (Reference)1921.0 (Reference)1481.0 (Reference)
    GA/AA3801371.0 (0.8-1.2)550.8 (0.6-1.1)470.9 (0.6-1.3)
    GA3311211.0 (0.8-1.3)510.9 (0.6-1.2)410.9 (0.6-1.4)
    AA49160.9 (0.5-1.6)40.4 (0.2-1.3)60.9 (0.4-2.2)
CYP1A2 (rs762551)
    AA7442651.0 (Reference)1381.0 (Reference)1011.0 (Reference)
    AC/CC7462901.1 (0.9-1.3)1110.8 (0.6-1.1)940.9 (0.7-1.3)
    AC6172371.1 (0.9-1.3)940.8 (0.6-1.1)740.9 (0.6-1.2)
    CC129531.1 (0.8-1.6)170.7 (0.4-1.2)201.1 (0.7-1.9)
NAT2
    Slow acetylator8803111.0 (Reference)1411.0 (Reference)1101.0 (Reference)
    Intermediate acetylator5292091.1 (0.9-1.4)941.1 (0.8-1.5)751.1 (0.8-1.5)
    Rapid acetylator80341.2 (0.8-1.9)120.9 (0.5-1.7)101.0 (0.5-2.0)
NAT1
    Slow acetylator69151.0 (Reference)111.0 (Reference)51.0 (Reference)
    Intermediate acetylator8063001.7 (0.9-3.0)1371.1 (0.5-2.1)1132.3 (0.9-6.2)
    Rapid acetylator6052381.8 (1.0-3.2)1001.0 (0.5-2.1)742.0 (0.8-5.5)
  • * Adjusted for age, sex, study site, educational attainment, indication for colonoscopy, smoking, alcohol consumption, physical activity, and regular NSAID use.

  • Definitions for imputation of NAT1 and NAT2 acetylator status are presented in Appendices 1 and 2.